Women Health Therapeutics Market to Reach $70.9 Billion by 2035

Women Health Therapeutics market was valued at $46.0 billion in 2025 and is expected to reach $70.9 billion by 2035, registering a CAGR of 4.5% during the forecast period from 2026 to 2035. The global women health therapeutics market is increasingly influenced by the high and persistent burden of cervical cancer, which remains one of the most common female?specific cancers. According to the World Health Organization, cervical cancer was the fourth most common cancer among women worldwide, with an estimated 660,000 new cases and about 350,000 deaths in 2022, highlighting ongoing unmet clinical need that therapeutics must address through prevention, early detection, and treatment strategies. This sustained disease load is prompting healthcare systems and pharmaceutical companies to expand screening, HPV vaccination programs, and advanced treatment options, reinforcing demand for therapeutics in infection?linked and oncology sub?segments of the women health market.

Browse the full report description of “Women Health Therapeutics Market Size, Share & Trends Analysis Report by Type (Infection, Pregnancy, Oncology, Menstrual & Hormonal Disorders, Osteoporosis & Bone Health, and Others), and by End-User (Hospitals & Clinics, Ambulatory Care Centers, Specialty Gynecology & Fertility Clinics, Home Healthcare & Telemedicine Services, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/women-health-therapeutics-market-size

• Cervical cancer accounts for approximately 660,000 new diagnoses annually, evidencing a large patient population requiring therapeutic intervention.
• Nearly 350,000 women died from cervical cancer in 2022, underscoring the mortality?related urgency for effective treatment options.
• The disease disproportionately affects low? and middle?income countries, reflecting global disparities that expand demand for accessible therapeutics.
• Persistent infection with high?risk human papillomavirus (HPV) causes almost all cases, linking infection management with oncology therapeutics demand.
• WHO targets (90?% vaccination, 70?% screening, 90?% treatment coverage) by 2030 indicate systemic scaling of preventive and therapeutic interventions.
• Expanded prevention and treatment efforts, including vaccination and early detection, are expected to further increase therapeutic uptake.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type
  • End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie Inc., Amgen Inc., Bayer AG, Cipla Limited, Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Women Health Therapeutics Market Report Segment

By Type

• Infection
• Pregnancy
• Oncology
• Menstrual & Hormonal Disorders
• Osteoporosis & Bone Health
• Others

By End-User

• Hospitals & Clinic
• Ambulatory Care Centers
• Specialty Gynecology & Fertility Clinics
• Home Healthcare & Telemedicine Services
• Others

Global Women Health Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/women-health-therapeutics-market-size